WEST PALM BEACH, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Onity Group Inc. (NYSE: ONIT) (“Onity” or the “Company”) today announced that it will hold a conference call on Thursday, November 6, 2025 at 8:30 a.m. (ET) to review the Company’s third quarter 2025 operating results and provide a business update. All interested parties are welcome to participate. You can access the conference call by dialing (833) 316-1983 or (785) 838-9310 approximately 10 minutes prior to the call; please reference the conference ...

Core Insights - GeneDx Holdings Corp. reported strong financial results for Q3 2025, highlighting significant growth in genomic testing and improved profitability metrics [2][7][8] - The company received FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ tests, emphasizing its leadership in genomic medicine [3][7][24] Financial Performance - Revenues reached $116.7 million, representing a 52% year-over-year increase [8] - Exome and genome test revenue grew to $98.9 million, a 65% increase year-over-year [8] - Adjusted gross margin expanded to 74%, up from 64% in Q3 2024, while GAAP gross margin was reported at 72% [4][8] - Adjusted net income for Q3 2025 was $14.7 million, compared to $2.0 million in Q3 2024, while GAAP net loss was $7.6 million [5][8] Operational Highlights - The volume of exome and genome tests increased by 33% year-over-year, totaling 25,702 tests [8] - Adjusted total operating expenses were $71.2 million, representing 61% of revenue, a slight decrease from 62% in Q3 2024 [8] - The company ended the quarter with a cash position of $156.1 million, including $8.8 million in free cash flow generated [8] Strategic Initiatives - GeneDx raised its full-year 2025 revenue guidance to between $425 million and $428 million, with expected growth in exome and genome revenue between 53% to 55% [7][9] - The company is leading genomic newborn screening initiatives, including participation in the NIH BEACONS initiative and a partnership with Florida's Sunshine Genetics Network [13] - GeneDx introduced GeneDx Infinity™, the largest rare disease dataset, enhancing its genomic testing capabilities [13][15] Market Position - GeneDx is positioned as a leader in genomic newborn screening, being the sole commercial testing provider for new programs [7][13] - The company is actively expanding its market presence and investing in sustainable growth with attractive margins [6][7]

Core Viewpoint - Nova Minerals Limited has initiated the procurement of essential mining and processing equipment for its Estelle starter antimony mining operations and downstream refinery at Port Mackenzie, Alaska, with the first production of military-grade antimony trisulfide expected in 2026/27 [1][6]. Equipment Procurement - All equipment is scheduled for delivery in the coming months, with transportation to the site planned via snow road in January 2026 [3]. - Key equipment purchases include two ore sorters, which demonstrated a 60.3% recovery rate of antimony from a 500 kg sample, significantly improving the feed grade from 15.2% to 35.2% Sb [3][4]. - One ore sorter will be installed at the Whiskey Bravo camp for processing stibnite ore stockpiles, while the second will be at the Port Mackenzie refinery site [4]. Strategic Objectives - The equipment purchases are aimed at advancing Nova's strategy to establish a fully integrated U.S. domestic antimony supply chain centered at Port Mackenzie, Alaska [5]. - The company is focused on securing a robust domestic supply chain for military-grade antimony, supported by a non-dilutive US$43.4 million award from the U.S. Department of War [6][7]. Financial Position - Nova has a strong balance sheet with approximately A$83.0 million in funding, including A$17.5 million in cash and the US$43.4 million award [9]. - These resources are expected to support the company's ambitious antimony and gold development programs without delay [9]. Exploration and Resource Development - The exploration team is advancing the broader Estelle Gold Project, with 2025 drilling and sampling programs completed and assays pending [9]. - An updated Mineral Resource Estimate is expected to further define Nova's growing gold and antimony portfolio in Alaska [9]. Market Position - Nova is positioned as a leader in the U.S. antimony production sector, bolstered by strong government support and increasing demand from partners for additional feedstock [7][8]. - The company aims to foster America's antimony independence while capitalizing on its first mover advantage in the market [8].

Maiden Drilling Program Reveals Visible Gold in Several HolesLONGUEUIL, Québec, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV: AZM) (OTCQX: AZMTF) announces that high-grade gold assay results have been obtained from channel sampling on the Rosa Zone (“Rosa”), which was discovered by prospecting this summer on the Company’s wholly owned Wabamisk Property (the “Property”) in the Eeyou Istchee James Bay (“James Bay”) region of Québec, Canada. In addition, several h ...

BEIJING, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cheer Holding, Inc. (NASDAQ: CHR) (“Cheer Holding” or the “Company”), a leading provider of advanced mobile internet infrastructure and platform services, today unveiled CHEERS Telepathy AI 3.0, a groundbreaking release that reimagines AI-powered creation. This major update delivers a full-stack technological revolution, ushering in a new era where professional-grade portrait photography seamlessly converges with dynamic content generation-all accessible through an ...

eShallgo, inc. Photo eShallgo, inc. Photo New York, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Shanghai, October 28, 2025 – Eshallgo Inc. ("Eshallgo" or the "Company") (Nasdaq: EHGO), a leading provider of integrated office and enterprise technology along with a suite of AI intelligence solutions in China, today announced that its U.S. subsidiary, Eshallgo USA Inc., has entered into a strategic partnership with Guangzhou Shangke Information Technology (Hong Kong) Co., Ltd., the global distributor of MAXSUN, one ...

Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD® U.S. net sales increased 10% to $431 million; total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.11 billion GAAP EPS of $13.62 and non-GAAP EPS(a) of $11.83; third quarter 2025 includes unfavorable $0.68 impact from acquired IPR&D chargeFDA approved Libtayo® as the first and only immunotherapy for high-risk adjuvant cutaneous sq ...

Core Insights - onsemi's Treo platform has been selected by Teledyne Technologies to develop next-generation readout integrated circuit (ROIC) ASICs for infrared imaging systems, emphasizing its advanced capabilities in aerospace, defense, security, and scientific applications [1][4]. Group 1: Technology and Features - The Treo platform is built on a 65nm node and features a modular architecture with a rich set of IP building blocks, which accelerates development and reduces time-to-market [2]. - Key features of the Treo platform include higher gate density for improved performance in a smaller footprint, lower power dissipation for enhanced efficiency, and dense on-chip energy storage for better signal integrity [7]. - The platform supports a wide temperature range, ensuring consistent performance in extreme conditions, and includes die stitching for large-format sensor designs [7]. Group 2: Strategic Importance - The Treo platform is manufactured in onsemi's East Fishkill, NY facility, which holds Category 1A Trusted Supplier accreditation, addressing the U.S. government's need for domestic chip manufacturing in support of national security [6]. - The platform's capabilities are critical for developing high-performance imaging sensors that operate reliably in harsh environments, which is essential for Teledyne's space products [5]. Group 3: Market Position and Future Outlook - onsemi is positioned to drive innovations in various megatrends, including vehicle electrification, sustainable energy grids, and industrial automation, with a focus on delivering intelligent power and sensing technologies [8]. - The collaboration with Teledyne Technologies highlights onsemi's role in advancing next-generation infrared imaging systems, which are vital for mission-critical applications [1][5].

Core Insights - Karolinska Development AB has invested SEK 7.5 million in BOOST Pharma's financing round, which totals SEK 15 million, aimed at advancing the clinical development of BT-101 for osteogenesis imperfecta [1][3][4] Company Overview - BOOST Pharma is a clinical-stage biopharmaceutical company focused on developing BT-101, a mesenchymal stem cell therapy for infants with osteogenesis imperfecta, a condition that leads to fragile bones and frequent fractures [2][3] - The financing will help BOOST Pharma accelerate its clinical program and work towards providing the first disease-modifying therapy for osteogenesis imperfecta [2] Clinical Development - Following positive results from the Phase 2 BOOSTB4 study, which demonstrated a reduction in fracture rate of over 75% in children with osteogenesis imperfecta, BOOST Pharma is preparing for a pivotal Phase 3 trial of BT-101 [3] - The BOOSTB4 trial indicated that BT-101 was safe and well-tolerated [3] Investment and Ownership - Karolinska Development's ownership stake in BOOST Pharma is 14% [4] - The financing round included equal participation from Industrifonden and Karolinska Development, highlighting collaborative investment efforts in the biopharmaceutical sector [3]

Core Viewpoint - ChemoMetec has upgraded its revenue and EBITDA guidance for the financial year 2025/26 due to increased interest in its technology, particularly the XcytoMatic platform [1][2]. Financial Performance - Revenue for the financial year 2025/26 is now expected to be in the range of DKK 565-580 million, an increase from the previously announced DKK 545-565 million [2]. - EBITDA is anticipated to be between DKK 320-335 million, up from the earlier forecast of DKK 295-315 million [2]. Company Overview - ChemoMetec develops, manufactures, and markets instruments for cell counting and various other measurements, targeting the pharmaceutical, biotech, and agricultural industries globally [3]. - The company serves some of the world's leading pharmaceutical companies [3]. - ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen [4].